Personalized neoantigen DC vaccine combined with camrelizumab following definitive therapy in locally advanced unresectable esophageal squamous cell carcinoma (CHANT-241): protocol for a randomized controlled trial
Authors
H. Eric Xu (ORCID: https://orcid.org/0000-0002-6829-8144)
Personalized neoantigen DC vaccine combined with camrelizumab following definitive therapy in locally advanced unresectable esophageal squamous cell carcinoma (CHANT-241): protocol for a randomized controlled trial
H. Eric Xu, Huashan Shi, Zheng Yt, Y.-P. Chen et al.
Journal
Frontiers in Immunology
Topics
Immunotherapy and Immune Responses
article
Personalized neoantigen DC vaccine combined with camrelizumab following definitive therapy in locally advanced unresectable esophageal squamous cell carcinoma (CHANT-241): protocol for a randomized controlled trial
H. Eric Xu, Huashan Shi, Zheng Yt, Y.-P. Chen, Zhenyu Ding, Wenjie Yang, Yang Li
article en
Abstract
No abstract available for this paper.
Publication Tag
Frontiers in ImmunologyVol. 16
Institutions
Sichuan University (CN), West China Hospital of Sichuan University (CN)
Funders
China Postdoctoral Science Foundation, Sichuan University, West China Hospital, Sichuan University
Ask Laika to Summarize, Analyze, and Connect papers live on the map.
Summarize Papers & Methodologies
Extract key findings, datasets, and comparative methods across publications.
Benchmark Rankings & Visual Analytics
Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.
Connect Distant Disciplines
Bridge topological clusters on the map to find hidden collaborative intersections.
Personalized neoantigen DC vaccine combined with camrelizumab following definitive therapy in locally advanced unresectable esophageal squamous cell carcinoma (CHANT-241): protocol for a randomized controlled trial — H. Eric Xu, Huashan Shi, et al. · Frontiers in Immunology (2026) | TGRS Research Map | TGRS